DE60234510D1 - 1h-indazolverbindungen die jnk hemmen - Google Patents

1h-indazolverbindungen die jnk hemmen

Info

Publication number
DE60234510D1
DE60234510D1 DE60234510T DE60234510T DE60234510D1 DE 60234510 D1 DE60234510 D1 DE 60234510D1 DE 60234510 T DE60234510 T DE 60234510T DE 60234510 T DE60234510 T DE 60234510T DE 60234510 D1 DE60234510 D1 DE 60234510D1
Authority
DE
Germany
Prior art keywords
group
group etc
indazone
hemmen
jnk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234510T
Other languages
English (en)
Inventor
Hitoshi Oinuma
Norihito Ohi
Nobuaki Sato
Motohiro Soejima
Hidenori Seshimo
Taro Terauchi
Takashi Doko
Naohiro Kohmura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Application granted granted Critical
Publication of DE60234510D1 publication Critical patent/DE60234510D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Paper (AREA)
DE60234510T 2001-04-16 2002-04-15 1h-indazolverbindungen die jnk hemmen Expired - Lifetime DE60234510D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001116521 2001-04-16
PCT/JP2002/003735 WO2002083648A1 (en) 2001-04-16 2002-04-15 Novel 1h-indazole compound

Publications (1)

Publication Number Publication Date
DE60234510D1 true DE60234510D1 (de) 2010-01-07

Family

ID=18967246

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234510T Expired - Lifetime DE60234510D1 (de) 2001-04-16 2002-04-15 1h-indazolverbindungen die jnk hemmen

Country Status (10)

Country Link
US (3) US6982274B2 (de)
EP (1) EP1380576B1 (de)
JP (1) JP4535680B2 (de)
KR (1) KR20040007497A (de)
CN (1) CN1300116C (de)
AT (1) ATE449763T1 (de)
AU (1) AU2002255263B2 (de)
CA (1) CA2440842A1 (de)
DE (1) DE60234510D1 (de)
WO (1) WO2002083648A1 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
EP1380576B1 (de) * 2001-04-16 2009-11-25 Eisai R&D Management Co., Ltd. 1h-indazolverbindungen die jnk hemmen
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
WO2003072550A1 (fr) 2002-02-28 2003-09-04 Eisai Co., Ltd. Nouveaux composes indazole a anneaux fusionnes
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
WO2004014368A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
TW200409759A (en) 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
EP1615636A1 (de) * 2003-04-10 2006-01-18 Pfizer Inc. Bicyclische verbindungen als nr2b-rezeptor-antagonisten
US7560467B2 (en) 2003-06-19 2009-07-14 Smithkline Beecham Corporation Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
KR20060119705A (ko) * 2003-07-30 2006-11-24 교와 핫꼬 고교 가부시끼가이샤 인다졸 유도체
CA2518951A1 (en) * 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. Protein kinase inhibitors
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
WO2005030776A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
WO2005035516A1 (ja) * 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
CA2546493A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Indazole compounds and methods of use thereof as protein kinase inhibitors
US7544707B2 (en) 2003-12-22 2009-06-09 Eli Lilly And Company Bicyclic derivatives as PPAR modulators
ATE455765T1 (de) * 2003-12-22 2010-02-15 Basilea Pharmaceutica Ag Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs
WO2005085206A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
US7378532B2 (en) 2004-03-26 2008-05-27 Yung Shin Pharmaceutical Ind. Co., Ltd. Fused pyrazolyl compound
GB0409080D0 (en) * 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
SG156685A1 (en) * 2004-07-27 2009-11-26 Sgx Pharmaceuticals Inc Fused ring heterocycle kinase modulators
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
AU2006209712B2 (en) * 2005-01-27 2011-06-09 Kyowa Hakko Kirin Co., Ltd. IGF-1R inhibitor
US7291614B2 (en) * 2005-02-24 2007-11-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR20080103996A (ko) * 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
MX2008012658A (es) 2006-03-31 2008-12-16 Schering Corp Inhibidores de cinasa.
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
CN101484426A (zh) 2006-06-30 2009-07-15 协和发酵麒麟株式会社 Aurora抑制剂
EP2036893A4 (de) 2006-06-30 2011-04-13 Kyowa Hakko Kirin Co Ltd Abl-kinase-inhibitor
DE102006030479A1 (de) * 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20080153810A1 (en) * 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
EP2134713A2 (de) * 2006-12-20 2009-12-23 Schering Corporation Neuartige jnk-hemmer
MX2009006864A (es) 2006-12-20 2009-08-28 Schering Corp Inhibidores novedosos de c jun-n-terminal cinasas.
US20100104567A1 (en) 2007-03-05 2010-04-29 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
EP2184987A4 (de) * 2007-07-31 2011-09-28 Burnham Inst Medical Research Bidentatverbindungen als kinasehemmer
JP5517935B2 (ja) 2007-08-17 2014-06-11 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール及びインダゾール化合物
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
MY152271A (en) * 2008-02-21 2014-09-15 Merck Sharp & Dohme Novel compounds that are erk inhibitors
EP2489660A1 (de) * 2008-03-20 2012-08-22 Abbott Laboratories Verfahren zum Herstellen von Mitteln für das zentrale Nervensystem, die TRPV1-Antagonisten sind
US20110278332A1 (en) * 2009-03-26 2011-11-17 Protexer, Inc. Shoe cover removal apparatus
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
WO2010111060A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US9035072B2 (en) 2010-04-22 2015-05-19 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
EP2584903B1 (de) * 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
EP2613782B1 (de) * 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
RU2617988C2 (ru) 2010-09-03 2017-05-02 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
WO2012078777A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
WO2012087772A1 (en) * 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2688886A1 (de) 2011-03-22 2014-01-29 Amgen Inc. Azolverbindungen als pim-inhibitoren
EP2766352B1 (de) * 2011-10-12 2018-06-06 University Health Network (UHN) Indazolverbindungen als kinasehemmer und verfahren zur krebsbehandlung damit
KR101511771B1 (ko) * 2011-12-20 2015-04-14 주식회사 엘지생명과학 세포괴사 저해제로서의 인돌 및 인다졸 화합물
PE20142258A1 (es) 2012-04-25 2015-01-15 Takeda Pharmaceutical Compuesto heterociclico nitrogenado
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US8980934B2 (en) 2012-06-22 2015-03-17 University Health Network Kinase inhibitors and method of treating cancer with same
WO2014010732A1 (ja) 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
TW201427970A (zh) * 2012-10-12 2014-07-16 Univ Health Network 激酶抑制劑及使用其治療癌症的方法
WO2014134774A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2964221B1 (de) 2013-03-04 2017-12-06 Merck Sharp & Dohme Corp. Verbindungen zur hemmung der enzymaktivität einer leucinreichen repeat-kinase
WO2014142255A1 (ja) 2013-03-14 2014-09-18 武田薬品工業株式会社 複素環化合物
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
EP3018123B1 (de) 2013-07-03 2023-05-10 Takeda Pharmaceutical Company Limited Amidverbindung
WO2015015519A1 (en) 2013-07-31 2015-02-05 Council Of Scientific & Industrial Research Novel indazole compounds and a process for the preparation thereof
US10351527B2 (en) 2014-04-09 2019-07-16 The University Of British Columbia Binding function 3 (BF3) site compounds as therapeutics and methods for their use
PL3424534T3 (pl) 2014-04-15 2021-11-22 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105061316B (zh) * 2015-07-17 2017-12-22 苏州大学 稠环类化合物、制备方法和用途
EP3337787B1 (de) * 2015-08-20 2021-03-03 JS InnoPharm (Shanghai) Ltd. 1h-pyrazolo[3,4-b]pyridin, 1h-thieno[2,3-c]pyrazol und 1h-indazole carboxamid-derivate und ähnliche verbindungen als extrazelluläre signal-regulierte kinase (erk) inhibitoren zur behandlung von krebs
KR102484810B1 (ko) * 2016-05-25 2023-01-05 (주)아모레퍼시픽 피부 미백용 조성물
WO2018151126A1 (ja) * 2017-02-14 2018-08-23 富士フイルム株式会社 インダゾール化合物の製造方法およびインダゾール化合物
WO2018188590A1 (en) * 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018234353A1 (en) * 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE
WO2018234354A1 (en) * 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
JP2021523118A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の塩
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
JP2022516057A (ja) 2018-12-31 2022-02-24 バイオメア フュージョン，エルエルシー メニン－ｍｌｌ相互作用の不可逆的阻害剤
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021050672A1 (en) * 2019-09-11 2021-03-18 Ohio State Innovation Foundation Kinase inhibitors for the treatment of neurodegenerative diseases
US20210094935A1 (en) * 2019-10-01 2021-04-01 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (de) 2019-12-04 2022-10-12 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CN113999211B (zh) * 2021-11-23 2022-11-29 郑州大学 一类特异性抗***癌活性的含1,2,3-三氮唑的吲唑骨架衍生物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1266763B (de) * 1965-07-27 1968-04-25 Kalle Ag Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten
JPS5944314B2 (ja) * 1975-01-15 1984-10-29 中外製薬株式会社 インダゾ−ル誘導体の製法
JPS604824B2 (ja) * 1976-04-02 1985-02-06 中外製薬株式会社 インダゾール誘導体
JPS5615287A (en) * 1979-07-16 1981-02-14 Chugai Pharmaceut Co Ltd Pyrazoloindazole derivative and its preparation
JPH01180878A (ja) * 1988-01-11 1989-07-18 Yoshitomi Pharmaceut Ind Ltd 縮合ピラゾール化合物
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
GB8811299D0 (en) * 1988-05-12 1988-06-15 Grayshan R Indazole derivatives
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
US5051430A (en) * 1990-09-10 1991-09-24 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1H-indazol-3-yl)-4-pyridinamines
JPH06206872A (ja) * 1992-10-06 1994-07-26 Yoshitomi Pharmaceut Ind Ltd 縮合型ピラゾール化合物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
JP2000501105A (ja) 1995-12-22 2000-02-02 デュポン ファーマシューティカルズ カンパニー 新規なインテグリン受容体アンタゴニスト
TR199802685T2 (xx) * 1996-06-25 1999-03-22 Pfizer Inc �kameli/katk�l� indazol t�revleri
SK6252000A3 (en) * 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
DE19821002A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2000000490A2 (en) 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
WO2000000491A1 (en) 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
EP1089993B1 (de) * 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonisten
US6133290A (en) * 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
JP2002527438A (ja) * 1998-10-09 2002-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４，５−ジヒドロ−イソオキサゾール誘導体及びそれらの製薬学的使用
CA2354591A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
KR20010108024A (ko) 1998-12-17 2001-12-07 프리돌린 클라우스너, 롤란드 비. 보레르 단백질 키나제 억제제로서의 4,5-피라진옥신돌
CA2354510A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
DE60041763D1 (de) 1999-04-23 2009-04-23 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
WO2000075118A1 (en) 1999-06-03 2000-12-14 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
JP2003531103A (ja) * 1999-08-12 2003-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＪＵＮＮ−末端キナーゼ（ＪＮＫ）および他のタンパク質キナーゼの阻害剤
KR100835700B1 (ko) 1999-08-19 2008-06-09 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를 함유하는 조성물
PL354515A1 (en) 1999-09-14 2004-01-26 Aventis Pharmaceuticals, Inc. Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as d4
EP1088815A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutisch Aktive Sulfonyl-Aminosäurederivate
EP1088821A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
EP1088822A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksame Sulfonyl Hydrazid-Derivate
EP1110957A1 (de) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazolderivate und ihre Verwendung als JNK Modulatoren
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
ES2317889T3 (es) * 2000-03-01 2009-05-01 Janssen Pharmaceutica Nv Derivados de tiazolilo 2,4-disustituido.
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
EP1380576B1 (de) * 2001-04-16 2009-11-25 Eisai R&D Management Co., Ltd. 1h-indazolverbindungen die jnk hemmen

Also Published As

Publication number Publication date
JP4535680B2 (ja) 2010-09-01
US20090203691A1 (en) 2009-08-13
CA2440842A1 (en) 2002-10-24
KR20040007497A (ko) 2004-01-24
WO2002083648A1 (en) 2002-10-24
US7541376B2 (en) 2009-06-02
AU2002255263B2 (en) 2006-12-14
CN1300116C (zh) 2007-02-14
JPWO2002083648A1 (ja) 2004-08-05
EP1380576A4 (de) 2005-02-16
US20040127538A1 (en) 2004-07-01
EP1380576B1 (de) 2009-11-25
US7776890B2 (en) 2010-08-17
US6982274B2 (en) 2006-01-03
US20050282880A1 (en) 2005-12-22
CN1512987A (zh) 2004-07-14
ATE449763T1 (de) 2009-12-15
EP1380576A1 (de) 2004-01-14

Similar Documents

Publication Publication Date Title
DE60234510D1 (de) 1h-indazolverbindungen die jnk hemmen
ATE327230T1 (de) Piperidinverbindungen und diese enthaltenden medikamente
DE60230266D1 (de) Phenylpyridincarbonyl piperazinderivate
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
NO20023456L (no) Nitrogenholdige forbindelser og farmasöytiske preparater inneholdende de samme
NO20033385L (no) Fuserte heterocykliske forbindelser
DE60129806D1 (de) Neue bizyklische verbindungen
SE0202838D0 (sv) Chemical compounds
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
ATE503746T1 (de) Neue imidazolidinderivate
ATE401311T1 (de) Kondensierte heterozyklische verbindungen als petidase inhibitoren
ID25649A (id) Turunan-turunan sikloalkena, produksi serta penggunaannya
MY140489A (en) 1,2-di (cyclic) substituted benzene compounds
ATE271045T1 (de) Sauerstoffhaltige heterocyclische verbindungen
DE60239170D1 (de) Bicyclische Verbindungen
DK1209151T3 (da) 4-substituerede piperidinderivativer
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
DE602004023873D1 (de) Verwendung davon
ATE465153T1 (de) Neue indazolverbindungen mit kondensiertem ring
SE0402461D0 (sv) New process
EP1557407A4 (de) Neue alpha-ketoamidderivate und deren verwendung
WO2003043735A3 (de) P-funktionalisierte amine n-haltiger aromaten, deren herstellung und ihre verwendung in katalytischen reaktionen
ATE404548T1 (de) Cyclisches hemiacetalderivat und dessen anwendung
TH65651A (th) สารประกอบมาโลโนไนไทรล์ และการใช้ของสิ่งดังกล่าว
DE60207709D1 (de) Verbindungen und methoden zur inhibierung von mrp1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition